Testimonial Working with the highly experienced and skillful accelopment team was crucial for the success of the EuroNeurotrophin project and will be instrumental in showcasing the project results and achievements.
Dr. Theodora Calogeropoulou
EuroNeurotrophin Project Coordinator,
National Hellenic Research Foundation, Greece

<< Projects


A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation

Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive.
The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation.
This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies.
The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.

National Hellenic Research Foundation, GR



Duration01.02.2014 – 31.01.2017
Budget3.2 million euro


We have more than 25 years of experience in FP7, Horizon 2020 and other funding programmes, from finding the best funding scheme, to proposal writing, project management and communication. accelopment has the expertise and the staff to support you from the inception of your research and innovative idea to the management of your funded project. We will be your sparring partner through all the steps including choosing the right call and funding scheme, proposal writing, the negotiation of your grant with the European Commission (EC), and maximising the impact of your R&D project. We also like to share our experience and offer several targetted training options.t for the boxes



I enjoy collaborating together with highly motivated researchers and team members to bring complex and innovative ideas closer to the targeted audience.

Julia Götz
Project Manager Communications